Updated Jul 16, 2026 · Last SEC filing 2026-07-06
LIGAND PHARMACEUTICALS INC (LGND) has filed 17 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-07-06. 8 Form 8-K material event filings were reported by LGND in the last 90 days. 10 Form 144 notices of proposed sale were filed for LGND stock. InsiderAlpha tracks every LGND SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.
| SIC classification | Pharmaceutical Preparations (SIC 2834) |
|---|---|
| SEC CIK | 0000886163 |
| Form 4 filings (90d) | 17 |
|---|---|
| Form 8-K filings (90d) | 8 |
| Form 144 notices (90d) | 10 |
| Latest Form 4 filing | 2026-07-06 |
| Date | Insider | Role | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Reardon Andrew | CLO & Secretary | M — Option exercise | 5.0K | $52.27 | $261K | SEC | |
| Reardon Andrew | CLO & Secretary | S — Open-market sale | 100 | $314.58 | $31K | SEC | |
| Reardon Andrew | CLO & Secretary | S — Open-market sale | 104 | $310.20 | $32K | SEC | |
| Reardon Andrew | CLO & Secretary | S — Open-market sale | 396 | $308.99 | $122K | SEC | |
| Reardon Andrew | CLO & Secretary | S — Open-market sale | 700 | $313.46 | $219K | SEC | |
| Reardon Andrew | CLO & Secretary | S — Open-market sale | 1.1K | $312.28 | $338K | SEC | |
| Reardon Andrew | CLO & Secretary | S — Open-market sale | 600 | $317.15 | $190K | SEC | |
| Reardon Andrew | CLO & Secretary | S — Open-market sale | 900 | $315.78 | $284K | SEC | |
| Reardon Andrew | CLO & Secretary | S — Open-market sale | 1.1K | $311.72 | $349K | SEC | |
| Davis Todd C | Chief Executive Officer | J — Other acquisition / disposition | 132 | $160.71 | $21K | SEC | |
| Espinoza Octavio | Chief Financial Officer | J — Other acquisition / disposition | 17 | $160.71 | $3K | SEC | |
| Reardon Andrew | CLO & Secretary | J — Other acquisition / disposition | 132 | $160.71 | $21K | SEC | |
| Sabba Stephen L | Director | M — Option exercise | 2.1K | $66.13 | $142K | SEC | |
| Sabba Stephen L | Director | S — Open-market sale | 2.1K | $254.00 | $545K | SEC | |
| Haas Jason | Director | S — Open-market sale | 3.5K | $256.08 | $886K | SEC |
All transactions sourced from SEC EDGAR Form 4 filings for LIGAND PHARMACEUTICALS INC (LGND). Updated in real time as new filings are submitted to the SEC.
| Insider | Form 4 filings | Total transaction value |
|---|---|---|
| Reardon Andrew | 29 | $4.66M |
| KOZARICH JOHN W | 13 | $704K |
| Haas Jason | 8 | $1.86M |
| LAMATTINA JOHN L | 6 | $1.15M |
| Sabba Stephen L | 5 | $687K |
Form 144 must be filed before insiders sell restricted or control stock above SEC thresholds. A cluster of Form 144 notices often precedes a wave of insider distribution.
SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in LGND insider filings:
| P | Open-market purchase by the insider |
|---|---|
| S | Open-market sale by the insider |
| A | Grant, award, or other acquisition from the issuer |
| M | Exercise or conversion of derivative security (e.g. options) |
| F | Payment of exercise price or tax liability via share withholding |
| G | Bona-fide gift of securities |
| D | Disposition to the issuer (e.g. share buyback participation) |
| J | Other acquisition or disposition |
| X | Exercise of in-the-money or at-the-money derivative security |
| C | Conversion of derivative security |
| V | Transaction voluntarily reported earlier than required |
Open the live LGND dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.